Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: A Pilot Study

Meagan O’Brien, MD1,2, Emilie Montenont, MS3, Liang Hu, PhD3, Michael A. Nardi, MA4, Vanessa Valdes, BS3, Michael Merolla, BS3, Gabrielle Gettenberg, BS3, Karen Cavanagh, RN2,5, Judith A. Aberg, MD2,5, Nina Bhardwaj, MD PhD6, and Jeffrey S. Berger MD, MS3

1 New York University, School of Medicine, Division of Infectious Diseases and Immunology, Cancer Institute, NY, NY
2 Bellevue Hospital Center, New York City Health and Hospital Corporation, New York, NY
3 New York University, School of Medicine, Divisions of Cardiology and Hematology, New York, NY
4 New York University, School of Medicine, Department of Pediatrics, Divisions of Hematology and Oncology, Pathology, New York, NY
5 New York University, School of Medicine, Division of Infectious Diseases and Immunology, New York, NY
6 New York University, School of Medicine, Divisions of Pathology, Dermatology, Cancer Institute, New York, NY

Corresponding author:
Meagan O’Brien
NYU Langone Medical Center
522 First Avenue
SML 1307
NY, NY 10016
Meagan.O’Brien@nyumc.org
Tel. 212-263-6727, Fax. 212-263-6729

Presented, in part, at the XIX International AIDS Conference, July 2012, Washington, DC, USA

Supported by the Center for AIDS Research pilot project grant P30 AI027742, in part by the NIAID Grant No. 5 U01 AI069532 (JA, KC), the Grunbaum AIDS research scholarship (MO), and by an American Heart Association Fellow to Faculty Award (0775074N) and a Doris Duke Clinical Scientist Development Award (2010055)(JSB).

M.O. designed the study and performed experiments, analyzed and interpreted data, and drafted and revised manuscript. G.G., L.H., M.M., E.M., V.V. and M.N. collected data and performed selected experiments. K.C. contributed to experimental design and collected data. J.A. and N.B. contributed to experimental design and revised manuscript. J.B. designed the study, analyzed and interpreted data, and drafted and revised the manuscript.

The authors have no conflicts of interest to disclose.

Running head: Aspirin in HIV Infection
ABSTRACT

Background: Mechanisms for increased cardiovascular risk in HIV-infected adults are incompletely understood, but platelet activation and immune activation leading to a pro-thrombotic state have been proposed as significant contributors. Aspirin has anti-platelet and immunomodulatory properties. We explored whether one week of low dose aspirin attenuates platelet activation and immune activation in HIV-infected and virologically suppressed adults on antiretroviral therapy (ART).

Methods: Platelet activation and immune activation were measured in HIV-infected subjects virologically suppressed on ART and controls before and after one week of low-dose aspirin.

Results: Compared to control subjects, HIV-infected subjects had increased platelet activation, as measured by spontaneous platelet aggregation and aggregation in response to adenosine diphosphate, collagen, and arachidonic acid (AA). Following aspirin therapy, percent aggregation decreased similarly in both HIV-infected and control subjects to all platelet agonists tested except aggregation in response to AA, which remained elevated in the HIV-infected group. HIV infected subjects exhibited increased markers of T-cell activation (CD38 and HLA-DR) and monocyte activation (sCD14), which decreased after one week of aspirin therapy. Moreover, leukocyte responses to Toll-like receptor stimulation were enhanced after one week of aspirin therapy. In vitro studies showed that HIV-plasma could activate healthy platelets, which in turn activated monocytes, implicating a direct role for activated platelets in immune activation.

Conclusions: Our data demonstrate that heightened platelet activation and immune activation in treated HIV disease are attenuated by one week of aspirin therapy. Aspirin should be further studied for its antithrombotic and immunomodulatory benefits in treated HIV disease.

Key Words: Platelets, HIV, Aspirin, Immune activation, aggregation
INTRODUCTION

HIV-1 (HIV) infected patients have an increased risk of ischemic cardiovascular events\(^1\)-\(^3\), but the pathogenic mechanisms underlying this risk remain elusive. Although antiretroviral therapy (ART) may contribute to cardiovascular risk due to its metabolic adverse effects\(^2\), HIV itself is an independent risk factor for cardiovascular events\(^4\)-\(^6\). These increased events correlate with increased markers of immune activation and inflammation, suggesting that a heightened inflammatory state in HIV contributes to thrombosis. Heightened immune activation correlates with disease progression in untreated HIV infection\(^7\),\(^8\) and persists, albeit to a lesser degree, in ART-treated HIV-infected patients and correlates with cardiovascular disease\(^9\).

Mechanisms that link immune activation, inflammation, and increased risk of thrombotic cardiovascular disease in HIV infection are incompletely understood. Recent studies have implicated platelet activation as a possible link. Circulating platelets in HIV-infected subjects have heightened expression of P-selectin, a molecule which binds P-selectin glycoprotein ligand-1 on endothelium and leukocytes and acts to recruit these cells to areas of injury and thrombosis\(^10\). Circulating platelet-monocyte complexes, another marker of platelet activation, are also elevated in HIV-infected subjects\(^11\). Notably, ART-treated subjects were not differentiated from viremic untreated subjects in these studies\(^10\),\(^16\). It is therefore unknown whether ART-treated and virologically suppressed subjects also manifest heightened platelet activation. Activated platelets have been implicated in thrombotic cardiovascular events because of their proinflammatory and thrombogenic effects\(^12\) and clinical studies have demonstrated the importance of platelet activity in coronary artery atherosclerosis and thrombosis. Platelet activity, measured by spontaneous platelet aggregation, provides information about platelet function, and is independently associated with long-term mortality and cardiovascular events\(^13\). Antiplatelet therapy is a cornerstone in the prevention of atherothrombotic events and its effects likely involve the modulation of inflammatory and immune pathways\(^12\),\(^14\),\(^15\),\(^16\). Therefore, we conducted an exploratory study to assess whether low dose aspirin in HIV-infected subjects virologically suppressed on ART would result in decreased platelet activity, immune activation and markers of inflammation.

METHODS

The study was conducted in accordance with policies of the New York University Langone Medical Center Institutional Review Board, Bellevue Hospital Center, and the central office of the New York City Health and Hospital Corporation.

Peripheral blood was drawn, with consent, from HIV-infected subjects (n=25) with HIV RNA viral load (VL) <50 copies/mL for at least 6 months on ART and from healthy controls (n=44). Exclusion criteria for this study included age < 18 years of age, NSAID use in the past week (including aspirin), renal failure (Cr Cl<30ml/min or on dialysis), history of myocardial infarction, coronary artery disease, diabetes, presence of co-existing inflammatory disease, co-existing cancer, active bacterial or fungal infection, predisposition to bleeding, or any antithrombotic therapy (e.g. coumadin, clostazol). Subjects were phlebotomized and urine was collected at baseline and after 7 days of aspirin, 325 mg loading dose followed by 81 mg daily. Subjects fasted overnight and refrained from intensive exercise and tobacco use for 4 hours prior to an early-morning phlebotomy and urine collection to avoid circadian variation in platelet response\(^17\). Blood was drawn using a 19-gauge needle. The first 2 mL was discarded, and the remaining blood was collected into tubes containing 3.2% sodium citrate for platelet activity and leukocyte studies.
Light Transmission Aggregometry
Light transmission aggregometry (LTA) was performed according to the manufacturer’s specification using Helena (Beaumont, TX, USA) AggRAM light transmission aggregometer. As previously described\(^1,^8\), functional assays of platelet activity in response to agonists at various concentrations: adenosine diphosphate (ADP; 0.4, 1 and 2µM), collagen (0.05, 0.2 and 1µg/mL), epinephrine (0.1, 0.4 and 2µM), or arachidonic acid (150 and 1500µM) and no agonist (spontaneous platelet aggregation [SPA]) were performed. Percent aggregation at 5 minutes and maximum percent aggregation at 10 minutes was recorded. All aggregation studies were completed within 2 hours of phlebotomy.

Urinary 11-dehydro-TXB\(_2\)
Urine samples were stored at -80°C until analysis. Urine samples were thawed and assayed for 11-dehydro thromboxane B\(_2\) with a commercially available enzyme immunoassay (Corgenix, Inc. Broomfield, Colorado).

Immune Activation
Fresh peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Hypaque (Amersham Pharmacia Biotech) from whole blood and were stained with antibodies from BD Pharmigen: CD8 FITC, HLADR PE, CD8 PerCP, CD38 APC, matching isotype controls for PE and APC, and fixed with 4% paraformaldehyde (Electron Microscopy Sciences). 100,000 events were acquired for each sample using BD FACSCalibur (BD Biosciences), and data was obtained using FlowJo Version 8.8.3 software (TreeStar).

Activating agonists
Fresh PBMCs were stimulated in duplicate at 1 million cells/200 µl media for 18 hours at 37°C, 5% CO\(_2\), with CpGB (5′-T*C*G*T*C*G*T*T*T*T*G*T*C*G*T*T*T*T*G*T*C*G*T*T*-3′, with asterisks denoting phosphorothioate bonds; 2 µg; IDT), LPS at 100 ng/mL (Sigma), or 300 ng p24\(^{CA}\) equivalents aldrithiol-2 (AT-2) HIV\(^{MN}\). AT-2–inactivated HIV-1 (AT-2 HIV) was prepared as described previously\(^19\).

Cytokine analysis
Plasma samples were stored at -80°C and were diluted 1:20 to 1:80 and were analyzed using cytometric bead array (BD Biosciences — Pharmingen) and multisubtype IFN-α ELISA kit (PBL Biomedical).

Inflammatory markers
Plasma samples were stored at -80°C. A commercial clinical laboratory performed assays for d-dimer (Stago assay), hs C-reactive protein (Siemens[Dade Behring] Nephelometry), and IL-6 (R&D). Plasma was diluted at 1:10 for soluble P-selectin (sP-selectin) and 1:200 for soluble CD14 (sCD14) and were measured using eBioscience and R&D kits respectively; all according to the manufacturer’s specification.

Plasma platelet activation and monocyte binding assay
Washed platelets. Whole blood from healthy donors was collected in 3.2% sodium citrate tubes and within 15 minutes was centrifuged at 200g for 10 minutes. The supernatant, containing platelet rich plasma (PRP), was collected, 100nM PGE-1 was added, and PRP was centrifuged at 800g for 10 minutes. Supernatant was discarded and Tyrode’s buffer (10mM Hepes,150mM NaCl, 2.5mM KCl,0.3mM NaH\(_2\)PO\(_4\), 12mMNaHCO\(_3\), 2mM EDTA and 0.1% Glucose, pH7.4) was added, containing 100nM PGE-1 to resuspend the platelet pellet at a concentration of 1.0x10\(^8\)platelets/uL.
Plasma. Blood from all study participants was collected into 3.2% sodium citrate tubes. For healthy donors, within 10 minutes after phlebotomy, 10uM epinephrine (positive control) or saline was added, incubated for 20 minutes, and then blood was centrifuged for 2500 g for 10 minutes. Supernatant plasma from healthy donors treated with or without epinephrine or supernatant plasma from HIV+ donors was collected and stored at -20°C.

Plasma platelet activation. 50uL of plasma was co-cultured with 5uL of fresh platelets (1.0x10^8 platelets/μL) and incubated for 30 minutes at 37°C. Platelets were washed to remove plasma at 800 g for 10 minutes. Platelets were labeled with anti CD61-FITC (Dako) and anti PAC-1 PE antibody or anti P-selectin PE antibody. Samples were analyzed by flow cytometry.

Monocyte binding assay. Washed platelets (1.0x10^5/μL) which had been activated with various plasma conditions were co-cultured with THP-1 monocytes (1.0x10^6/μL) for 30 minutes at 37°C. Cells were fixed and stained for anti CD61-FITC and anti CD14-PE and analyzed by flow cytometry.

Statistical Analysis
2 tailed paired Student’s t-tests or Wilcoxon Signed-Rank test were used for paired analyses comparing subjects before and after aspirin. Unpaired 2 tailed Student’s t-tests or Mann Whitney U tests were used for unpaired analyses. Spearman’s correlation and chi-square tests were used for analyses of associations.

RESULTS

Subject demographics

<table>
<thead>
<tr>
<th></th>
<th>HIV-infected (n=25)</th>
<th>Uninfected control (n=44)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex (n, %)</td>
<td>19, 76%</td>
<td>21, 48%</td>
</tr>
<tr>
<td>Median age (n, range)</td>
<td>50 (31-71)</td>
<td>27 (21-60)</td>
</tr>
<tr>
<td>BMI(n, range)</td>
<td>23.5 (18.9-43.5)</td>
<td>23.6 (18-32.9)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>11, 44%</td>
<td>25, 57%</td>
</tr>
<tr>
<td>Black</td>
<td>13, 52%</td>
<td>1, 2%</td>
</tr>
<tr>
<td>Asian</td>
<td>0, 0%</td>
<td>15, 34%</td>
</tr>
<tr>
<td>Other</td>
<td>1, 4%</td>
<td>3, 7%</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>11, 44%</td>
<td>3, 7%</td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td>14, 56%</td>
<td>41, 93%</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current Smoker</td>
<td>14, 56%</td>
<td>2, 5.7%</td>
</tr>
<tr>
<td>Mean years since HIV diagnosis (n, range)</td>
<td>9.5 (1-26)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mean years of effective ART (n, range)</td>
<td>6 (0.5-21)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mean CD4 count (n, range)</td>
<td>630 (181-1124)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mean CD4 nadir (n, range)</td>
<td>166 (5-422)</td>
<td>N/A</td>
</tr>
<tr>
<td>Current antiretroviral usage</td>
<td>9 NNRTI-based</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>13 PI-based</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4Raltegravir-based</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 Abacavir-containing</td>
<td></td>
</tr>
</tbody>
</table>

Median age of HIV-infected was 50 (range, 31 to 71). Nearly 50% of the population was white and 76% were male. 56% were current smokers. Mean CD4+T cell count was 630 (range 181-1124), mean CD4+T cell count nadir was 166 (range 5-422). Mean years of HIV diagnosis was 9.5 (range 1-26) and mean years on effective ART therapy with a suppressed HIV RNA viral load was 6 (range 0.5-21). All subjects with HIV had platelet counts within the normal range (195x10^3/ml [IQR, 164, 241]). Current ART regimens are listed in Subject demographics.
ART-treated HIV-infected subjects have hyper-reactive platelets

Prior data\textsuperscript{20} demonstrate that the use of sub-maximal concentrations of agonists identify subjects with a hyper-reactive platelet phenotype. HIV-infected subjects evidenced significantly higher median spontaneous platelet aggregation (SPO) (7.9\% [4.6, 11.8] vs 4.9\% [2.4, 8.4], p=0.045) and higher median aggregation in response to all sub-maximal agonist concentrations (ADP 0.4uM, 11.3\% [6.6, 44.4] vs 6.4\% [2.8, 9.7], p=0.003; Collagen (COL) 0.05ug/ml, 5.6\% [3.9, 12.4] vs 3.2\% [1.8, 6.2], p=0.001; and AA 150uM, 54.9\% [8.2, 89.9] vs 7.4\% [3.0, 31.0], p=0.003) except epinephrine (EPI) 0.1uM 81.2\% [17.0-91;3] vs 78.8\% [13.0-90.7], p=0.672, than uninfected controls. At higher agonist concentrations, much of the differences observed between HIV infected subjects and healthy controls were attenuated (Table 1).

Effects of aspirin on platelet activity in ART-treated HIV-infected subjects

Platelet aggregation was measured 24 hours after a loading dose of aspirin 325mg in HIV-infected subjects and then again following one week of aspirin 81mg daily in both the HIV-infected subjects and the healthy controls. As compared to baseline, platelet aggregation was significantly inhibited following a single dose of 325mg in HIV-infected subjects and following one week of aspirin in both groups (controls were not available for single dose measurements) (see Table S1, Supplemental Digital Content, http://links.lww.com/QAI/A399). As compared to the control group, HIV-infected subject platelet aggregation was inhibited similarly after one week of aspirin to all platelet agonists tested except aggregation in response to low and high-dose AA, which remained elevated in the HIV-infected group (150uM, 9.7\% [5.5, 15.2] vs 6.1\% [4.5, 9.1], p=0.007, and AA 1500uM, 22.2\% [16.4, 46.1] vs 12\% [7.6, 21.7], p=0.002) (Table 1).

Urinary thromboxane is higher in HIV-infected subjects and is less responsive to aspirin therapy

Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), inhibiting the formation of the potent platelet agonist thromboxane. To further assess platelet activity and the adequacy of COX-1 inactivation by aspirin ex vivo, we measured urinary excretion of the major enzymatic metabolite of thromboxane, 11-dehydro-thromboxane (TX) B\textsubscript{2}. The basal level of median urinary concentration of 11-dehydro thromboxane B\textsubscript{2} was significantly higher in HIV-infected subjects compared with controls (9626.8 vs7295.2 pg/mL, p=0.02). After one week of aspirin, 11-dehydro thromboxane B\textsubscript{2} decreased significantly in both groups but remained significantly higher in the HIV-infected group (2255.7 vs 1422.6 pg/mL, p=0.04) (Figure 1A).

ART-treated HIV-infected subjects have increased soluble P-selectin, which is decreased after a week of aspirin therapy

Soluble P-selectin (sP-selectin) is a biomarker for platelet/endothelial activation and is considered a risk factor for vascular disease\textsuperscript{21}. sP-selectin enhances procoagulant activity by inducing leukocyte-derived microparticle production and promotes activation of leukocyte integrins. There was a trend for higher median sP-selectin in HIV-infected as compared to uninfected control subjects at baseline (58.2 ng/mL vs. 54.1 ng/mL) and a significant decrease in median sP-selectin in HIV-infected patients after one week of aspirin (58.2 ng/mL vs. 47.7ng/mL) but not after one day (58.2 ng/mL vs. 54.3 ng/mL)(Figure 1B).

T-cell and monocyte immune activation is higher in ART-treated HIV-infected subjects than uninfected control subjects and is decreased after one week of aspirin therapy

Previous studies have shown that immune activation in ART-treated HIV-infected subjects is higher than in uninfected control subjects but lower than in untreated HIV-infected subjects \textsuperscript{22,23}. Because aspirin has been shown to have immunomodulatory properties\textsuperscript{24,25}, we tested whether aspirin may affect T-cell or monocyte activation markers. T cell activation was evaluated by
measuring activation markers CD38 and HLA-DR on CD4+ and CD8+ lymphocytes. In accordance with prior studies, we found that immune activation is higher in HIV-infected subjects on ART than uninfected control subjects. HIV-infected subjects had significantly higher %CD4+HLADR+CD38+ lymphocytes than uninfected control subjects (median 8.95% vs. 4.4%, p=0.001) and there was a trend for higher %CD8+HLADR+CD38+ lymphocytes in HIV-infected than uninfected control subjects (median 9.98% vs. 6.95%, p=0.13). In response to one week of aspirin, there was a significant decrease in HIV-infected subjects' CD4+HLADR+CD38+ lymphocytes (median 8.95% vs 6.81%, p=0.005) and CD8+HLADR+CD38+ lymphocytes (median 9.98% vs 6.70%, p=0.015) but not in uninfected control subjects' CD4+HLADR+CD38+ lymphocytes (median 4.40% vs 4.19%) and CD8+HLADR+CD38+ lymphocytes (median 6.95% vs 6.42%) (Figure 2A, B).

Monocyte activation was tested by analyzing soluble CD14 (sCD14) levels in plasma. sCD14 levels were higher in treated HIV-infected subjects as compared to uninfected control subjects at baseline (median 2.60x10^6 vs 1.26x10^6 pg/mL; p<0.001) and sCD14 decreased significantly in treated HIV-infected subjects after a week of aspirin (median 2.60x10^6 vs 2.49x10^6 pg/mL; p<0.001) and in uninfected control subjects (median 1.26x10^6 vs 1.04x10^6 pg/mL; p<0.009) (Figure 2C). T-cell activation correlated moderately with monocyte activation (r=0.43; p=0.06) (Figure 2D). These data demonstrate that HIV-infected subjects have increased levels of T-cell and monocyte activation, which subsequently decreases after a week of low-dose aspirin therapy. In this small study, there were no significant associations between aspirin-mediated improvement in T cell activation (CD4+HLADR+CD38+ or CD8+HLADR+CD38+) or monocyte activation and the following subject characteristics: age, gender, CD4 count, CD4 nadir, smoking status, years since HIV diagnosis, years on effective ART, or ART drug class (data not shown).

One week of aspirin enhances responsiveness of leukocytes to TLR agonist stimulation
Innate immune cells are less responsive to Toll-like receptor (TLR) stimulation during chronic HIV-infection26,27, possibly as a result of chronic stimulation by inflammatory cytokines 26,28. Because aspirin is anti-inflammatory, we tested whether one week of aspirin therapy would improve leukocyte TLR-agonist responsiveness in HIV subjects. PBMCs from HIV-infected subjects on ART or uninfected control PBMCs were stimulated with relevant TLR 7, 9, and 4 agonists HIV, CpGB or LPS, respectively, for 18 hours and compared to un-stimulated PBMCs. After one week of aspirin therapy no differences were observed in mean spontaneous production of cytokines (IL-6, TNFα, IL-1β, and IFNα) by PBMCs from HIV-infected subjects. However, in response to CpGB or HIV stimulation, after one week of aspirin PBMCs from HIV-infected subjects produced higher levels of IL-6 (mean 108.5 vs 92.8 ng/mL, p=0.01 and 107.6 vs 76.9 ng/mL, p=0.01 respectively), and a trend towards enhanced production of TNFα in response to CpGB or LPS (mean 11.3 vs 7.3 ng/mL, p=0.06 and 38.1 vs 24.1, p=0.07 respectively)(Figure 3). There were no improvements in TLR responsiveness after one week of aspirin of PBMCs from HIV-infected subjects to produce IL1β or IFNα. In uninfected controls there was no significant change either in the spontaneous production of cytokines after overnight incubation or in response to TLR stimulation after one week of aspirin in the uninfected control PBMCs. For example, in response to CpGB or HIV stimulation, control PBMCs produced similar levels of IL-6 before and after aspirin (mean 73.8 vs 76.7 ng/mL, p=0.73 and 97.7 vs 107.3 ng/mL, p=0.57 respectively), and similar levels of TNFα in response to CpGB or LPS before and after aspirin (mean 8.7 vs 10.6 ng/mL, p=0.36 and 13.6 vs 13.3, p=0.85 respectively. Our data indicate that one week of low-dose aspirin 81 mg daily partly ameliorates the defect in TLR responsiveness in PBMCs from HIV-infected subjects.
One week of aspirin does not change soluble inflammation markers
Markers of inflammation IL-6, d-dimer, and CRP are elevated in HIV disease, correlate with morbidity and mortality, and are somewhat reduced with ART, but remain elevated when compared with levels in HIV-uninfected persons. We investigated whether inflammatory markers decrease after a week of low dose aspirin therapy in treated HIV-infected patients. Median levels of CRP, d-dimer, and IL-6 decreased non-significantly after one week of aspirin therapy (2.7 mg/L [0.8, 3.9] vs. 2.2 mg/L [0.8-3.2]), (0.23 mcg/mL [0, 0.36] vs. 0.13 mcg/mL [0, 0.38]), and 2.03 pg/mL [1.18, 2.31] vs. 1.98 pg/mL [1.15, 3.68]).

Plasma from HIV-infected subjects activates platelets and HIV-plasma activated platelets activate monocytes
To investigate the mechanism of platelet activation in HIV-infected subjects, we exposed platelets from healthy controls to plasma from our HIV-infected cohort. Contrary to results with healthy control plasma, plasma from our HIV-infected control cohort induced platelet activation, as assessed by increased surface expression of PAC-1 and P-selectin. Platelet activation after incubation with HIV-infected plasma was inhibited if the HIV plasma donor had received 1-week of daily aspirin. We next incubated the plasma-activated platelets with THP-1 monocytes. We hypothesized that activated platelets contribute to monocyte activation in HIV disease. Platelets which were cultured with plasma from HIV-infected subjects were able to activate THP-1 monocytes, as evidenced by the formation of platelet monocyte aggregates. HIV-plasma-activated platelets caused formation of platelet monocyte aggregates significantly more than healthy control-activated platelets. The formation of platelet monocyte aggregates in this assay was significantly abrogated by aspirin therapy, indicating that soluble plasma factors may play a role in platelet hyper-reactivity and innate immune activation in HIV infection, which may be reversed by aspirin therapy (Figure 4).

Altogether we present new data that platelets from treated and virologically suppressed HIV-infected subjects are hyper-reactive spontaneously and in response to platelet-activating agonists. We show that one week of daily aspirin 81mg is effective in decreasing platelet activity in HIV-infected and uninfected controls. We also present the intriguing findings that aspirin may reverse immune activation in treated HIV infection and enhance leukocyte responses to TLR agonists. We show that platelets from healthy donors are activated by HIV plasma. In turn, HIV-plasma-activated platelets contribute to monocyte activation, suggesting that soluble plasma factors in HIV-infected subjects play a role in platelet activation and secondarily in leukocyte activation. Together, these data support the conclusion that platelet activity is increased in virologically suppressed HIV-infected subjects. Moreover, increased platelet activation may contribute to immune activation, as both platelet and immune activation are ameliorated by aspirin therapy.

DISCUSSION
HIV-infected patients have a heightened risk of cardiovascular disease, including myocardial infarction and sudden cardiac death. Although traditional cardiovascular risk factors and antiretroviral medications may contribute to this risk, emerging data suggests a role for immune activation and dysfunction. Multiple studies have shown that low CD4+ T cell counts are associated with cardiovascular events and increased immune activation has been associated with increased carotid artery lesions. The link between immune activation and cardiovascular risk in HIV disease remains incompletely understood, but platelet activation may play an important role.
In this study we found that platelets from HIV-infected subjects are significantly more reactive spontaneously and to low-dose platelet activating agonists than are platelets from uninfected control subjects. At the highest doses of platelet activating agonists, however, platelets from both HIV-infected and uninfected control subjects aggregated maximally and no differences were observed. This data suggests that platelets from HIV-infected subjects have a lower threshold to activation, but that this hyper-reactivity is dose-dependent. When activated platelets are maximally stimulated with platelet agonists \textit{ex vivo}, they demonstrate a blunted response, presumably related to the platelets having undergone intragranular release \textit{in vivo}\textsuperscript{36}. This phenomenon has been termed “exhausted platelets”\textsuperscript{37}. In addition, as evidenced by ineffective platelet inhibition to AA and elevated urinary thromboxane metabolites after aspirin, COX-1 mediated platelet reactivity remains higher in patients with HIV than uninfected controls, suggesting that longer duration and/or higher dose of aspirin therapy may be needed to completely suppress COX-1 mediated platelet reactivity in ART-treated HIV-infected individuals.

One week of low-dose aspirin also decreased markers of T-cell and monocyte activation and augmented leukocyte responsiveness to certain TLR-agonist stimuliants. Healthy platelets incubated with plasma from HIV-infected subjects became activated, however, plasma from HIV-infected subjects that had been taking aspirin for one week attenuated this platelet activation. Furthermore, HIV-plasma-activated-platelets potently activated monocytes, implicating a direct role for activated platelets in immune activation. Importantly, platelets incubated with HIV-plasma from subjects who had taken aspirin for one week had a significant reduction in monocyte activation. Therefore, activated platelets may contribute to monocyte activation in HIV infection. The close interaction between platelets and monocytes may help explain the relationship between platelet activity and inflammation, thereby providing a better understanding of the increased cardiovascular risk in HIV-infected subjects.

As an anti-platelet and immunomodulating agent, aspirin may diminish immune activation in HIV disease 1) indirectly, through inhibition of platelet activation and 2) directly, through blocking inflammatory pathways in multiple cell types. Platelets express toll-like receptor (TLR) 2, 4, and 9\textsuperscript{38} and can become activated in response to pro-inflammatory cytokines or infective bacterial agents\textsuperscript{39,40}, both of which are elevated in HIV infection. Platelets are anucleate; however, they contain a substantial amount of mRNA and all of the translational machinery necessary to rapidly generate their own proteins during hemostatic and inflammatory events. Activated platelets express CD154 (CD40L) and P-selectin which can in turn activate multiple cell types, including endothelial cells, neutrophils, monocytes, and dendritic cells, to produce inflammatory cytokines and chemokines\textsuperscript{41,42}. The enhanced leukocyte responses we observed following aspirin use are consistent with prior reports. Aspirin has been shown to directly enhance TNF$\alpha$ release from LPS-activated RAW264.7 (macrophage) cells\textsuperscript{43}. As observed in this study, aspirin therapy may reverse this inhibition of cytokine production by inhibiting platelet activation.

This small pilot study provides evidence that activated platelets may contribute to immune activation and inflammation in HIV infection. Importantly, this study also suggests that low-dose aspirin may be a potential intervention for HIV-infected subjects on ART to blunt platelet and immune activation and inflammation. As this study was a small non-randomized open-label pilot study, future studies are needed to confirm and expand upon our findings.
ACKNOWLEDGEMENTS

We gratefully acknowledge the tireless efforts of the late Luis Vargas for recruitment of study participants. We would like to thank the NYU/Bellevue ACTU study nurses Janet Forcht RN, Caroline Sturm-Reganato RN, and Richard Hutt RN for clinical trial services and student volunteers Stuart Sacks, Lindsay Elbaum, and Christopher Lopez for data collection and study sample transport.

REFERENCES


Figure legends:

Figure 1: Urinary thromboxane is higher in HIV-infected subjects and is less responsive to aspirin therapy. **A.** Urinary 11-dehydro-TXB$_2$ levels were higher in HIV(+) subjects as compared to HIV(-) control subjects at baseline, (*p=0.02) and after 1-week of aspirin (*p=0.04), Mann Whitney test. **B.** Plasma P-selectin levels decreased in ART-treated HIV-infected subjects after one week of aspirin, paired t-test, *p<0.05. P-selectin levels do not decrease in uninfected control subjects after one week of aspirin.

Figure 2: T cell activation is increased in ART-treated HIV-infected subjects and decreases after a week of aspirin therapy. Fresh PBMCs were isolated from blood from HIV(+) subjects and HIV(-) control subjects and were stained for markers of immune activation, fixed, and analyzed by flow cytometry. **A.** HLADR+CD38+ CD4+ and **B.** HLADR+CD38+CD8+ lymphocytes decrease significantly after one week of aspirin therapy, paired t-test, *p<0.05. ART-treated HIV-infected subjects have elevated sCD14, which is decreased after one week of aspirin. **C.** Both HIV(+) and HIV(-) subjects experienced a decrease in sCD14 after one week of aspirin therapy, paired t-test, *p<0.05. **D.** sCD14 correlated with CD8+ lymphocyte immune activation, r=0.43; p=0.06.

Figure 3: One week of aspirin therapy improves responsiveness of leukocytes to certain TLR agonists. Fresh PBMCs were incubated overnight with TLR agonists CpG and HIV and culture supernatants were stored at -20°C. Cytokine Bead Array analyses were performed on culture supernatants by flow cytometry. After 1-week of aspirin, more IL-6 was produced in response to CpGB p=0.01, more IL-6 was produced in response to HIV p=0.01, and more TNFα was produced in response to CpGB p=0.06 (all using paired t-tests).

Figure 4: Plasma from HIV-infected subjects activates platelets and HIV-plasma activated platelets activate monocytes. Normal platelets from 5 donors were incubated with control plasma at 37° for 30 min +/- epinephrine (epi) or plasma from 5 donor HIV study subjects before and after 1 wk aspirin. Normal platelets mixed with plasma from HIV subjects expressed higher platelet activation markers **A.** PAC-1 and **B.** P-selectin at baseline, (*p<0.05, Mann Whitney test) but this was abrogated when HIV-plasma was used from subjects receiving 1-wk of aspirin therapy (paired student’s t-test, *p<0.05). **C.** These activated platelets caused THP-1 monocytes to activate more, as measured by CD14+CD61+ double-staining aggregates, Mann Whitney test *p<0.05, but this effect was also abrogated after 1-wk aspirin therapy (paired student’s t-test, *p<0.05).

Supplementary figure 1: HIV-infected and healthy control subjects have a bimodal response to sub-maximal concentrations of platelet agonists. Within 30 minutes of phlebotomy, fresh platelet-rich plasma was isolated and was stimulated with low-dose arachidonic acid, ADP, epinephrine, collagen, or no stimulation (spontaneous platelet aggregaton) and analysed by light transmission aggregometry. Representative platelet aggregometry results are shown, Mann Whitney U test, *p<0.05.
Table 1. ART-treated HIV-infected subjects have hyper-reactive platelets

<table>
<thead>
<tr>
<th>Baseline % platelet aggregation</th>
<th>1 week aspirin % platelet aggregation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV</td>
</tr>
<tr>
<td>ADP 0.4uM 300s</td>
<td>4.0 (1.0-12.0)</td>
</tr>
<tr>
<td>ADP 0.4uM MAX</td>
<td>11.3 (6.6-44.4)</td>
</tr>
<tr>
<td>1uM 300s</td>
<td>35.0 (10.0-87.0)</td>
</tr>
<tr>
<td>1uM MAX</td>
<td>59.3 (25.8-88.3)</td>
</tr>
<tr>
<td>2uM 300s</td>
<td>81.0 (42.0-92.0)</td>
</tr>
<tr>
<td>2uM MAX</td>
<td>84.3 (52.5-93.5)</td>
</tr>
<tr>
<td>COL 0.05ug/ml 300s</td>
<td>2.0 (0.0-7.5)</td>
</tr>
<tr>
<td>COL 0.05ug/ml MAX</td>
<td>5.6 (3.9-12.4)</td>
</tr>
<tr>
<td>COL 0.2ug/ml 300s</td>
<td>8.5 (0.0-83.5)</td>
</tr>
<tr>
<td>COL 0.2ug/ml MAX</td>
<td>12.6 (4.3-88.2)</td>
</tr>
<tr>
<td>COL 1ug/ml 300s</td>
<td>84.0 (80.0-88.0)</td>
</tr>
<tr>
<td>COL 1ug/ml MAX</td>
<td>87.4 (81.4-90.7)</td>
</tr>
<tr>
<td>EPI 0.1uM 300s</td>
<td>22.0 (9.0-80.0)</td>
</tr>
<tr>
<td>EPI 0.1uM MAX</td>
<td>81.2 (17.0-91.3)</td>
</tr>
<tr>
<td>EPI 0.4uM 300s</td>
<td>79.5 (36.8-89.0)</td>
</tr>
<tr>
<td>EPI 0.4uM MAX</td>
<td>89.2 (81.4-95.2)</td>
</tr>
<tr>
<td>EPI 2uM 300s</td>
<td>83.0 (76.3-91.5)</td>
</tr>
<tr>
<td>EPI 2uM MAX</td>
<td>86.6 (78.3-93.4)</td>
</tr>
<tr>
<td>AA 150uM 300s</td>
<td>3.0 (1.5-13.8)</td>
</tr>
<tr>
<td>AA 150uM MAX</td>
<td>54.9 (8.2-89.9)</td>
</tr>
<tr>
<td>AA 1500uM 300s</td>
<td>88.5 (83.5-90.0)</td>
</tr>
<tr>
<td>AA 1500uM MAX</td>
<td>90.4 (86.3-93.0)</td>
</tr>
<tr>
<td>SPO 300s</td>
<td>3.0 (1.0-8.0)</td>
</tr>
<tr>
<td>SPO MAX</td>
<td>7.9 (4.6-11.8)</td>
</tr>
</tbody>
</table>
Figure 1.

A. Urinary thromboxane

B. P-selectin

* indicates statistical significance.
Figure 2.

A. CD4+ lymphocytes

B. CD8+ lymphocytes

C. Soluble CD14

D. CD8+HLA-DR/CD38+
Figure 3.

[Graphs showing cytokine levels in CpGB and HIV before and after aspirin intake.]

Copyright © Lippincott Williams & Wilkins. All rights reserved.
Figure 4.